Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INDACATEROL

All products: Limited Use (codes 443)

Other products in the same Health Canada class (R03A, R03AC) — coverage varies; not interchangeable

  • Salbutamol (Teva-Salbutamol Sterinebs P.F.): general benefit, Limited Use 256, 257, 258, 259, Limited Use 265, 266, 267, 268, Not a benefit
  • Terbutaline (Bricanyl Turbuhaler): general benefit
  • Formoterol (Foradil): limited Use 132
  • Formoterol (Oxeze Turbuhaler): limited Use 132
  • Salmeterol (SereVent Diskus): limited Use 132, 391
  • Aclidinium + formoterol (Duaklir Genuair): limited Use 459

7 more in the class list below

Onbrez Breezhaler · DIN 02376938 · 75mcg · Inh Pd-capsule

Limited Use — Reason for Use code 443 required; Health Canada lists this DIN as Cancelled post market since 2023-05-12 — choose a marketed DIN from the same-category list.Discontinued 2023-05-12 · checked 2026-09-19
StatusLimited Use — Reason for Use code 443 required; Health Canada lists this DIN as Cancelled post market since 2023-05-12 — choose a marketed DIN from the same-category list.
Write on scriptLU code 443 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2023-05-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 443
Reason for Use code 443 For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic. Note: The dose of Onbrez Breezhaler should not exceed 75mcg per day. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Onbrez Breezhaler · DIN 02376938 Manufacturer: Novartis Pharma Canada Inc.; listing date 2013-04-30 Health Canada: Cancelled post market since 2023-05-12 · brand ONBREZ BREEZHALER · ATC R03AC18 INDACATEROL · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL MALEATE) 75 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Onbrez Breezhaler: Formulary list price $1.5500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.5500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86250 · Verify on the e-Formulary ↗ (DIN 02376938)

Source record
DIN 02376938: Onbrez Breezhaler Raw flags: sec12=Y, sec3=Y Item: 121200104; group id 228; item number 0407; lccId 00231; manufacturer id NOV Source form: Inh Pd-Cap; strength: 75mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.5500; ministry $1.5500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02376938 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86250
Shortage status: discontinued (2022-07-01, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02376938
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-05-12 — choose a marketed DIN from the same-category list.

INDACATEROL & GLYCOPYRRONIUM

All products: Limited Use (codes 459)

Other products in the same Health Canada class (R03A, R03AC) — coverage varies; not interchangeable

  • Salbutamol (Teva-Salbutamol Sterinebs P.F.): general benefit, Limited Use 256, 257, 258, 259, Limited Use 265, 266, 267, 268, Not a benefit
  • Terbutaline (Bricanyl Turbuhaler): general benefit
  • Formoterol (Foradil): limited Use 132
  • Formoterol (Oxeze Turbuhaler): limited Use 132
  • Salmeterol (SereVent Diskus): limited Use 132, 391
  • Aclidinium + formoterol (Duaklir Genuair): limited Use 459

7 more in the class list below

Ultibro Breezhaler · DIN 02418282 · 110mcg & 50mcg · Inh Pd-capsule

Limited Use — Reason for Use code 459 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 459 required
Write on scriptLU code 459 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 459
Reason for Use code 459 For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)). Coverage limit: LU Authorization Period: Indefinite Coverage limit: COPD disease severity is based on spirometry, symptoms and disability (see classification tables below). Classification COPD Stages - Symptoms and disability: Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill. Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure Classification by impairment of lung function: COPD stage and spirometry (post bronchodilator) FEV1 predicted: Mild: Greater than or equal to 80 percent Moderate: 50 to 79 percent Severe: 30 to 49 percent Very severe: Less than 30 percent
No interchangeable product listed in the Ontario extract
Ultibro Breezhaler · DIN 02418282 Manufacturer: Novartis Pharma Canada Inc.; listing date 2015-05-28 Health Canada: Marketed since 2014-03-05 · brand ULTIBRO BREEZHALER · ATC R03AL04 INDACATEROL AND GLYCOPYRRONIUM BROMIDE · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL MALEATE) 110 MCG, GLYCOPYRRONIUM (GLYCOPYRROLATE) 50 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ultibro Breezhaler: Formulary list price $2.5830/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.5830 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90285 · Verify on the e-Formulary ↗ (DIN 02418282)

Source record
DIN 02418282: Ultibro Breezhaler Raw flags: sec12=Y, sec3=Y Item: 121200108; group id 229; item number 0408; lccId 00252; manufacturer id NOV Source form: Inh Pd-Cap; strength: 110mcg & 50mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.5830; ministry $2.5830 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02418282 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90285
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02418282
Shortage record checked 2026-09-13T08:10:21.292534+00:00

INDACATEROL ACETATE & GLYCOPYRRONIUM BROMIDE & MOMETASONE FUROATE

All products: Limited Use (codes 627)

Other products in the same Health Canada class (R03A, R03AC) — coverage varies; not interchangeable

  • Salbutamol (Teva-Salbutamol Sterinebs P.F.): general benefit, Limited Use 256, 257, 258, 259, Limited Use 265, 266, 267, 268, Not a benefit
  • Terbutaline (Bricanyl Turbuhaler): general benefit
  • Formoterol (Foradil): limited Use 132
  • Formoterol (Oxeze Turbuhaler): limited Use 132
  • Salmeterol (SereVent Diskus): limited Use 132, 391
  • Aclidinium + formoterol (Duaklir Genuair): limited Use 459

7 more in the class list below

Enerzair Breezhaler · DIN 02501244 · 150mcg & 50mcg & 160mcg · Inh Pd-capsule

Limited Use — Reason for Use code 627 requiredMarketed · checked 2026-09-18
StatusLimited Use — Reason for Use code 627 required
Write on scriptLU code 627 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 627
Reason for Use code 627 For the treatment of asthma in adult patients inadequately controlled with a maintenance combination of a long-acting beta-2 agonist (LABA) and a medium or high dose of an inhaled corticosteroid (ICS), who experienced one or more asthma exacerbations in the previous 12 months. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Enerzair Breezhaler · DIN 02501244 Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28 Health Canada: Marketed since 2020-11-05 · brand ENERZAIR BREEZHALER · ATC R03AL12 INDACATEROL, GLYCOPYRRONIUM BROMIDE AND MOMETASONE · form Capsule · route Inhalation · ingredients MOMETASONE FUROATE 160 MCG, INDACATEROL (INDACATEROL ACETATE) 150 MCG, GLYCOPYRRONIUM (GLYCOPYRROLATE) 50 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Enerzair Breezhaler: Formulary list price $3.4277/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.4277 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99087 · Verify on the e-Formulary ↗ (DIN 02501244)

Source record
DIN 02501244: Enerzair Breezhaler Raw flags: sec12=Y, sec3=Y Item: 680400122; group id 713; item number 1763; lccId 00355; manufacturer id NOV Source form: Inh Pd-Cap; strength: 150mcg & 50mcg & 160mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.4277; ministry $3.4277 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02501244 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99087
Shortage status: resolved shortage (ended 2024-05-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02501244
Shortage record checked 2026-09-13T08:10:21.292534+00:00

INDACATEROL ACETATE & MOMETASONE FUROATE

All strengths: Limited Use — Reason for Use code 626 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 626 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (R03A, R03AC) — coverage varies; not interchangeable

  • Salbutamol (Teva-Salbutamol Sterinebs P.F.): general benefit, Limited Use 256, 257, 258, 259, Limited Use 265, 266, 267, 268, Not a benefit
  • Terbutaline (Bricanyl Turbuhaler): general benefit
  • Formoterol (Foradil): limited Use 132
  • Formoterol (Oxeze Turbuhaler): limited Use 132
  • Salmeterol (SereVent Diskus): limited Use 132, 391
  • Aclidinium + formoterol (Duaklir Genuair): limited Use 459

7 more in the class list below

Atectura Breezhaler · DIN 02498685 · 150mcg & 80mcg · Inh Pd-capsule

Limited Use — Reason for Use code 626 requiredMarketed · checked 2026-09-19
Write on scriptLU code 626 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 626
Reason for Use code 626 For once-daily maintenance treatment of asthma in patients aged 12 years and older with reversible obstructive airways disease. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Atectura Breezhaler · DIN 02498685 Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28 Health Canada: Marketed since 2020-08-19 · brand ATECTURA BREEZHALER · ATC R03AK14 INDACATEROL AND MOMETASONE · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL ACETATE) 150 MCG, MOMETASONE FUROATE 80 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Atectura Breezhaler: Formulary list price $1.0731/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.0731 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98847 · Verify on the e-Formulary ↗ (DIN 02498685)

Source record
DIN 02498685: Atectura Breezhaler Raw flags: sec12=Y, sec3=Y Item: 680400119; group id 714; item number 1766; lccId 00354; manufacturer id NOV Source form: Inh Pd-Cap; strength: 150mcg & 80mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.0731; ministry $1.0731 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498685 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98847
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02498685
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Atectura Breezhaler · DIN 02498693 · 150mcg & 320mcg · Inh Pd-capsule

Limited Use — Reason for Use code 626 requiredMarketed · checked 2026-09-19
Write on scriptLU code 626 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 626
Reason for Use code 626 For once-daily maintenance treatment of asthma in patients aged 12 years and older with reversible obstructive airways disease. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Atectura Breezhaler · DIN 02498693 Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28 Health Canada: Marketed since 2020-08-19 · brand ATECTURA BREEZHALER · ATC R03AK14 INDACATEROL AND MOMETASONE · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL ACETATE) 150 MCG, MOMETASONE FUROATE 320 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Atectura Breezhaler: Formulary list price $1.8473/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.8473 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98848 · Verify on the e-Formulary ↗ (DIN 02498693)

Source record
DIN 02498693: Atectura Breezhaler Raw flags: sec12=Y, sec3=Y Item: 680400121; group id 714; item number 1765; lccId 00354; manufacturer id NOV Source form: Inh Pd-Cap; strength: 150mcg & 320mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.8473; ministry $1.8473 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498693 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98848
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02498693
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Atectura Breezhaler · DIN 02498707 · 150mcg & 160mcg · Inh Pd-capsule

Limited Use — Reason for Use code 626 requiredMarketed · checked 2026-09-19
Write on scriptLU code 626 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 626
Reason for Use code 626 For once-daily maintenance treatment of asthma in patients aged 12 years and older with reversible obstructive airways disease. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Atectura Breezhaler · DIN 02498707 Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28 Health Canada: Marketed since 2020-08-19 · brand ATECTURA BREEZHALER · ATC R03AK14 INDACATEROL AND MOMETASONE · form Capsule · route Inhalation · ingredients INDACATEROL (INDACATEROL ACETATE) 150 MCG, MOMETASONE FUROATE 160 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Atectura Breezhaler: Formulary list price $1.3419/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3419 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98849 · Verify on the e-Formulary ↗ (DIN 02498707)

Source record
DIN 02498707: Atectura Breezhaler Raw flags: sec12=Y, sec3=Y Item: 680400120; group id 714; item number 1764; lccId 00354; manufacturer id NOV Source form: Inh Pd-Cap; strength: 150mcg & 160mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.3419; ministry $1.3419 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498707 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98849
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02498707
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (12:12 Sympathomimetic (Adrenergic) Agents) and how they are covered

Matched class: 12:12 Sympathomimetic (Adrenergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE, SALBUTAMOL 12:12 Sympathomimetic (Adrenergic) Agents

SALBUTAMOL

· 20 products · Limited Use, codes 265, 266, 267, 268 (4), Listed, not a benefit (8), Limited Use, codes 256, 257, 258, 259 (1), General benefit (7) · strengths: 1mg/mL, 2mg/mL, 5mg/mL, 100mcg/Metered Dose, 2mg, 4mg · Inh Sol- 2.5mL Pk, Inh Sol-10mL Pk, Inh-200 dose Pk, Tab

TERBUTALINE SULFATE

· 2 products · General benefit · strengths: 0.5mg/Dose · Inh-100 Dose Pk, Inh-120 Dose Pk

FORMOTEROL FUMARATE

· 1 products · Limited Use, codes 132 · strengths: 12mcg/Cap · Inh Pd-Device Pk

FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 132 · strengths: 6mcg/Metered Dose, 12mcg/Metered Dose · Pd Inh-60 Dose Pk

SALMETEROL XINAFOATE

· 1 products · Limited Use, codes 132, 391 · strengths: 50mcg · Pd Inh-60 Dose Pk

ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 459 · strengths: 400mcg & 12mcg · Metered Dose Pd Inh-60 Dose Pk

BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg/6mcg, 200mcg/6mcg · Pd Inh-120 Dose Pk

BUDESONIDE&GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE)&FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 638 · strengths: 160mcg & 7.2mcg & 5mcg/Act · Metered Dose Inh-120 Dose Pk

FLUTICASONE FUROATE & UMECLIDINIUM BROMIDE & VILANTEROL TRIFENATATE

· 1 products · Limited Use, codes 567 · strengths: 100mcg & 62.5mcg & 25mcg · Pd Inh-30 Dose Pk

FLUTICASONE FUROATE & VILANTEROL

· 2 products · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) · strengths: 100mcg & 25mcg, 200mcg & 25mcg · Blister Pd Inh-30 Dose Pk

MOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg & 5mcg, 200mcg & 5mcg · Metered Dose Inh-120 Dose Pk

SALMETEROL XINAFOATE & FLUTICASONE PROPIONATE

· 11 products · Limited Use, codes 330 · strengths: 25/125mcg/Metered Dose, 25/250mcg/Metered Dose, 50/100mcg, 50/250mcg, 50/500mcg · Inh-120 Dose Pk, Inh-60 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:12 and 3 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:20 Skeletal Muscle Relaxants

Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

MOMETASONE FUROATE

· 3 products · General benefit · strengths: 400mcg/Metered Dose, 200mcg/Metered Dose · Pd Inh-30 Dose Pk, Pd Inh-60 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 4 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: asthma, obstructive pulmonary disease
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, GLYCOPYRRONIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM FLUTICASONE FUROATE & VILANTEROL · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) INDICATIONS AND CLINICAL USE COPD BREO ELLIPTA (fluticasone furoate/vilanterol) 100/25 mcg is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations. PM: https://pdf.hres.ca/dpd_pm/00049111.PDF; date January 7, 2019; DIN 02408872; fetched 2026-09-10 Product monograph Page 3 of 74 Asthma BREO ELLIPTA 100/25 mcg and BREO ELLIPTA 200/25 mcg are indicated for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. PM: https://pdf.hres.ca/dpd_pm/00049111.PDF; date January 7, 2019; DIN 02408872; fetched 2026-09-10 Product monograph ACLIDINIUM BROMIDE · General benefit INDICATIONS AND CLINICAL USE TUDORZA GENUAIR (aclidinium bromide) is indicated as a long-term maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00067375.PDF; date not captured; DIN 02409720; fetched 2026-09-10 Product monograph ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 459 INDICATIONS AND CLINICAL USE DUAKLIR GENUAIR (aclidinium bromide/formoterol fumarate dihydrate) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA) indicated as a long-term maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. PM: https://pdf.hres.ca/dpd_pm/00067361.PDF; date not captured; DIN 02439530; fetched 2026-09-10 Product monograph BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 330 INDICATIONS AND CLINICAL USE Asthma SYMBICORT TURBUHALER (budesonide and formoterol fumarate dihydrate) is indicated for the treatment of asthma in patients 12 years and older with reversible obstructive airways disease. PM: https://pdf.hres.ca/dpd_pm/00059997.PDF; date February 8, 2021; DIN 02245385; fetched 2026-09-10 Product monograph GLYCOPYRRONIUM BROMIDE · General benefit 1 INDICATIONS SEEBRI ® BREEZHALER ® (glycopyrronium bromide) is indicated as a long-term once-daily maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00067963.PDF; date October 16, 2012; DIN 02394936; fetched 2026-09-10 Product monograph MOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 330 1 Indications ZENHALE® (mometasone furoate / formoterol fumarate dihydrate inhalation aerosol), is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) indicated for: • the treatment of asthma, in patients 12 years of age and older with reversible obstructive airway disease. PM: https://pdf.hres.ca/dpd_pm/00080784.PDF; date 2025-06-09; DIN 02361752; fetched 2026-09-10 Product monograph TIOTROPIUM BROMIDE MONOHYDRATE · General benefit 1 INDICATIONS SPIRIVA (tiotropium bromide monohydrate) is indicated for:  long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. PM: https://pdf.hres.ca/dpd_pm/00065560.PDF; date NOV 20, 2002; DIN 02246793; fetched 2026-09-10 Product monograph TIOTROPIUM BROMIDE MONOHYDRATE & OLODATEROL HYDROCHLORIDE · Limited Use, codes 459 INDICATIONS AND CLINICAL USE INSPIOLTO RESPIMAT (tiotropium bromide monohydrate and olodaterol hydrochloride) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA) indicated for the long term, once daily maintenance bronchodilator treatment of airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00054220.PDF; date November 14, 2019; DIN 02441888; fetched 2026-09-10 Product monograph UMECLIDINIUM · General benefit 1 INDICATIONS INCRUSE ELLIPTA (umeclidinium) is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00072581.PDF; date April 8, 2014; DIN 02423596; fetched 2026-09-10 Product monograph UMECLIDINIUM & VILANTEROL · Limited Use, codes 459 1 INDICATIONS ANORO ELLIPTA (umeclidinium/vilanterol) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA) indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00069868.PDF; date March 14, 2014; DIN 02418401; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
1 INDICATIONS ULTIBRO BREEZHALER (indacaterol maleate and glycopyrronium bromide) is a combination of a long- acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and for the reduction of exacerbations of COPD in patients with a history of exacerbations. ULTIBRO BREEZHALER is not indicated for the treatment of acute episodes of bronchospasm. ULTIBRO BREEZHALER is not indicated for asthma use. The safety and effectiveness of ULTIBRO BREEZHALER in asthma have not been established. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): No dosage adjustment is required in patients over 65 years of age. https://pdf.hres.ca/dpd_pm/00072513.PDF PM date: Dec 23, 2013 Source product: ULTIBRO BREEZHALER; DIN 02418282; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS ENERZAIR BREEZHALER (indacaterol / glycopyrronium / mometasone furoate) is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta 2 -agonist and a medium or high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous 12 months. ENERZAIR BREEZHALER is not indicated for the relief of acute bronchospasm (see General). 1.1 Pediatrics Pediatrics (<18 years of age): The safety and efficacy of ENERZAIR BREEZHALER in pediatric patients below 18 years of age have not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): No dose adjustment is required in patients 65 years of age or older (see 10.3 Pharmacokinetics). https://pdf.hres.ca/dpd_pm/00063748.PDF PM date: Jul 2, 2020 Source product: ENERZAIR BREEZHALER; DIN 02501244; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS ATECTURA BREEZHALER (indacaterol/mometasone furoate) is a combination of a long-acting beta2- adrenergic agonist (LABA) and an inhaled corticosteroid (ICS) indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease. ATECTURA BREEZHALER should be prescribed for patients not adequately controlled on a long-term asthma control medication, such as ICS or whose disease severity clearly warrants treatment with both a LABA and an ICS. ATECTURA BREEZHALER is not indicated for patients whose asthma can be managed by occasional use of a rapid onset, short duration, inhaled beta2-agonist or for patients whose asthma can be successfully managed by ICS along with occasional use of a rapid onset, short duration, inhaled beta2-agonist. ATECTURA BREEZHALER is not indicated for the relief of acute bronchospasm (see General). 1.1 Pediatrics Pediatrics (under 12 years of age): The safety and efficacy of ATECTURA BREEZHALER in pediatric patients less than 12 years of age has not been established, therefore, Health Canada has not authorized an indication for this age group. 1.2 … https://pdf.hres.ca/dpd_pm/00063537.PDF PM date: May 5, 2020 Source product: ATECTURA BREEZHALER; DIN 02498685; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Onbrez Breezhaler · DIN 02376938 Shortage status: discontinued (2022-07-01, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02376938

Check this DIN again